TG4050
One patient, one cancer, one vaccine
With TG4050, Transgene is developing an individualized immunotherapy based on multiple advanced genetic engineering technologies and cutting-edge artificial intelligence capabilities, together with NEC.
Once injected into the patient, the vaccine induces a specific immune response, enabling individualized targeted destruction of tumor cells.
Two clinical trials are including patients in the USA, in the UK and in France.
myvac® video 